INT29743

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1988
Last Reported 2011
Negated 2
Speculated 3
Reported most in Abstract
Documents 91
Total Number 95
Disease Relevance 65.56
Pain Relevance 31.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (App) Golgi apparatus (App) plasma membrane (App)
extracellular matrix organization (App) DNA binding (App) cytoplasm (App)
Anatomy Link Frequency
brain 7
plaque 5
plasma 4
neuronal 4
cleavage 2
App (Mus musculus)
Pain Link Frequency Relevance Heat
Abeta 355 100.00 Very High Very High Very High
Eae 32 100.00 Very High Very High Very High
Dorsal horn 4 100.00 Very High Very High Very High
cINOD 284 99.92 Very High Very High Very High
Multiple sclerosis 53 99.48 Very High Very High Very High
qutenza 6 99.38 Very High Very High Very High
Hippocampus 346 99.24 Very High Very High Very High
noradrenaline 3 99.08 Very High Very High Very High
agonist 64 99.06 Very High Very High Very High
dexamethasone 37 98.68 Very High Very High Very High
Disease Link Frequency Relevance Heat
Targeted Disruption 1759 100.00 Very High Very High Very High
Alzheimer's Dementia 1619 100.00 Very High Very High Very High
Cognitive Disorder 444 100.00 Very High Very High Very High
Immunization 32 99.96 Very High Very High Very High
Disease 2389 99.92 Very High Very High Very High
INFLAMMATION 742 99.80 Very High Very High Very High
Neurodegenerative Disease 285 99.68 Very High Very High Very High
Aging 75 99.68 Very High Very High Very High
Amyloid Plaque 513 99.64 Very High Very High Very High
Demyelinating Disease 57 99.48 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Post-hoc analysis showed that ibuprofen-dependent reductions of both soluble Abeta and Abeta42 were most marked in entorhinal cortex (p < 0.05).
Negative_regulation (reductions) of Abeta in cortex associated with abeta
1) Confidence 0.59 Published 2001 Journal Neurobiol. Aging Section Abstract Doc Link 11755007 Disease Relevance 0.42 Pain Relevance 0.32
We show that ibuprofen reduced Abeta brain levels in rats from exogenously infused Abeta in the absence of altered Abeta production.
Negative_regulation (reduced) of Abeta in brain associated with abeta
2) Confidence 0.55 Published 2005 Journal Neuropsychopharmacology Section Abstract Doc Link 15688088 Disease Relevance 0.75 Pain Relevance 0.62
With low-dose but not high-dose curcumin treatment, the astrocytic marker GFAP was reduced, and insoluble beta-amyloid (Abeta), soluble Abeta, and plaque burden were significantly decreased by 43-50%.
Negative_regulation (decreased) of Abeta in plaque associated with alzheimer's dementia and abeta
3) Confidence 0.51 Published 2001 Journal J. Neurosci. Section Abstract Doc Link 11606625 Disease Relevance 0.92 Pain Relevance 0.54
NSAIDs activate the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma); however, a potent agonist of this receptor, pioglitazone, only modestly reduced SDS-soluble Abeta levels and did not affect amyloid plaque burden or microglia activation, indicating that PPARgamma activation is not involved in the Abeta lowering effect of NSAIDs.
Negative_regulation (reduced) of Abeta in plaque associated with agonist, cinod, amyloid plaque and abeta
4) Confidence 0.50 Published 2003 Journal J. Neurosci. Section Abstract Doc Link 12930788 Disease Relevance 0.95 Pain Relevance 0.75
These data show that chronic NSAID treatment can reduce brain Abeta levels, amyloid plaque burden, and microglial activation in an animal model of Alzheimer's disease.
Negative_regulation (reduce) of Abeta in plaque associated with cinod, disease, amyloid plaque and abeta
5) Confidence 0.50 Published 2003 Journal J. Neurosci. Section Abstract Doc Link 12930788 Disease Relevance 0.81 Pain Relevance 0.60
The remaining eight PS1 FAD mutants showed either no reduction of Abeta(42) or only rather subtle effects.
Neg (no) Negative_regulation (reduction) of Abeta associated with alzheimer's dementia and abeta
6) Confidence 0.47 Published 2008 Journal J. Biol. Chem. Section Abstract Doc Link 17962197 Disease Relevance 0.67 Pain Relevance 0.75
Similar observations were made for fenofibrate, a compound known to increase Abeta(42) and to decrease Abeta(38).
Negative_regulation (decrease) of Abeta associated with abeta
7) Confidence 0.47 Published 2008 Journal J. Biol. Chem. Section Abstract Doc Link 17962197 Disease Relevance 0.68 Pain Relevance 0.78
Modulation of gamma-secretase activity by sulindac sulfide reduced Abeta(42) in the case of wild type PS1 and two FAD-associated PS1 mutations (M146L and A285V).
Negative_regulation (reduced) of Abeta associated with alzheimer's dementia and abeta
8) Confidence 0.47 Published 2008 Journal J. Biol. Chem. Section Abstract Doc Link 17962197 Disease Relevance 0.70 Pain Relevance 0.68
This reduction in oxidative stress is associated with significant decreases in levels of amyloid-beta (Abeta) 40 and 42 peptides and amyloid deposition.
Negative_regulation (decreases) of Abeta associated with stress, alzheimer's dementia and abeta
9) Confidence 0.44 Published 2005 Journal J. Neurosci. Section Abstract Doc Link 16267225 Disease Relevance 1.44 Pain Relevance 0.32
production by decreasing intracellular transport of APP, prolonging the availability of APP for cleavage by ?
Negative_regulation (decreasing) of APP in cleavage
10) Confidence 0.43 Published 2011 Journal Mol Brain Section Body Doc Link PMC3022812 Disease Relevance 0 Pain Relevance 0
NAA is considered to be a good marker of neuronal viability; its decrease in APP(xPS1) mice might be caused by the intraparenchymal accumulation of A?
Negative_regulation (decrease) of APP in neuronal
11) Confidence 0.43 Published 2010 Journal International Journal of Alzheimer's Disease Section Body Doc Link PMC2952791 Disease Relevance 1.22 Pain Relevance 0.20
Importantly, both APPswe/ind and APP–C-terminal fragment levels were fully suppressed after only 1 wk of treatment, indicating that the in vivo half-life of APPswe/ind and its processed C-terminal fragments are relatively short (Figure 3D).
Negative_regulation (suppressed) of APP
12) Confidence 0.43 Published 2005 Journal PLoS Medicine Section Body Doc Link PMC1283364 Disease Relevance 0.60 Pain Relevance 0
APP is developmentally regulated with maximal expression during synaptogenesis and subsequently declines when mature connections are completed [48,49].
Negative_regulation (declines) of APP
13) Confidence 0.43 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1808499 Disease Relevance 0.44 Pain Relevance 0
These types of deficit, some of which exhibit very early onset [57, 310] have been observed in the PDAPP [53], Tg2576 [137, 329], APP23 [163, 181, 310], TgCRND8 [57], and crossed APP/PS1 [198] models.
Negative_regulation (crossed) of APP
14) Confidence 0.43 Published 2007 Journal Acta Neuropathol Section Body Doc Link PMC2100431 Disease Relevance 0.60 Pain Relevance 0.10
Furthermore, we will focus on the more relevant therapeutical strategies currently used, namely those involving antioxidants, drugs for neurotransmission improvement, hormonal replacement, gamma- and beta- secretase inhibitors, Abeta clearance agents (Abeta immunization, disruption of Abeta fibrils, modulation of the cholesterol-mediated Abeta transport), non-steroidal anti-inflammatory drugs (NSAIDs), microtubules stabilizing drugs and kinase inhibitors.
Negative_regulation (disruption) of Abeta associated with inflammation, immunization, cinod and abeta
15) Confidence 0.43 Published 2005 Journal Curr Drug Targets CNS Neurol Disord Section Abstract Doc Link 16101556 Disease Relevance 0.94 Pain Relevance 0.48
The dysregulation in the metabolism of beta-amyloid precursor protein and consequent deposition of amyloid-beta (Abeta) has been envisaged as crucial for the development of neurodegeneration in Alzheimer's disease (AD).
Negative_regulation (deposition) of Abeta associated with alzheimer's dementia, disease and abeta
16) Confidence 0.42 Published 2003 Journal Drugs Aging Section Abstract Doc Link 12534311 Disease Relevance 0.64 Pain Relevance 0.15
The dysregulation in the metabolism of beta-amyloid precursor protein and consequent deposition of amyloid-beta (Abeta) has been envisaged as crucial for the development of neurodegeneration in Alzheimer's disease (AD).
Negative_regulation (deposition) of amyloid-beta associated with alzheimer's dementia, disease and abeta
17) Confidence 0.42 Published 2003 Journal Drugs Aging Section Abstract Doc Link 12534311 Disease Relevance 0.64 Pain Relevance 0.15
Statins also warrant further investigation, since they have activated alpha-secretase and they reduced Abeta generation and amyloid accumulation in a transgenic mouse model. beta-Secretase would seem to be an ideal target for anti-amyloid therapy in AD, but potential clinical and pharmacological issues, such as ensuring selectivity of inhibition, stability, and ease of blood-brain barrier penetration and cellular uptake, remain to be addressed for beta-secretase inhibitors. gamma-Secretase is not an easy candidate for pharmacological manipulation.
Negative_regulation (reduced) of Abeta in brain associated with targeted disruption, alzheimer's dementia, disease and abeta
18) Confidence 0.42 Published 2005 Journal Drugs Aging Section Abstract Doc Link 16506440 Disease Relevance 1.07 Pain Relevance 0.29
The finding that AdoMet levels in APP/PS1 mice are not decreased during aging (in contrast to wild-type mice), is probably related to less demand due to neurodegeneration.
Neg (not) Negative_regulation (decreased) of APP associated with aging
19) Confidence 0.42 Published 2009 Journal Neurol Sci Section Abstract Doc Link PMC2746292 Disease Relevance 0.66 Pain Relevance 0
The loss of NA was also associated with increased cognitive deficits in APP23 tg animals.
Negative_regulation (deficits) of APP23 associated with cognitive disorder and noradrenaline
20) Confidence 0.42 Published 2008 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC2755760 Disease Relevance 0.36 Pain Relevance 0.62

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox